Xeris Biopharma (NASDAQ:XERS) Announces Earnings Results, Beats Estimates By $0.01 EPS

Posted by Scott Davis on Aug 11th, 2024

Xeris Biopharma (NASDAQ:XERS – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01, Zacks reports. The firm had revenue of $48.07 million for the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative net margin of 37.58% and a negative return on equity of 16,662.63%. During the same period last year, the company posted ($0.14) EPS. Xeris Biopharma updated its FY 2024 guidance to EPS.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS traded up $0.09 during trading on Friday, hitting $2.32. The company’s stock had a trading volume of 2,486,568 shares, compared to its average volume of 1,773,283. The business has a 50 day moving average price of $2.29 and a two-hundred day moving average price of $2.28. The company has a market capitalization of $343.96 million, a PE ratio of -4.94 and a beta of 2.72. Xeris Biopharma has a fifty-two week low of $1.46 and a fifty-two week high of $3.26.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Xeris Biopharma in a research note on Friday, May 31st. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of Xeris Biopharma in a research note on Friday, May 10th.

Check Out Our Latest Stock Report on XERS

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.